Retroviral Integrase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 80: | Line 80: | ||
| [[Elvitegravir]] || - || [http://www.gilead.com/ Gilead Science] || - || GS-9137 interacts with Pro 214 of PFV intasome through its quinolone base and isopropyl group. In experimental stages; shares the core structure of quinolone antibiotics. [http://clinicaltrials.gov/ct2/show/NCT00707733 Phase II] studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past. | | [[Elvitegravir]] || - || [http://www.gilead.com/ Gilead Science] || - || GS-9137 interacts with Pro 214 of PFV intasome through its quinolone base and isopropyl group. In experimental stages; shares the core structure of quinolone antibiotics. [http://clinicaltrials.gov/ct2/show/NCT00707733 Phase II] studies of elvitegravir in people who are treatment experienced have been completed. Phase III studies in treatment experienced patients are ongoing. A phase II study of elvitegravir in people who have never taken antiretroviral therapy is underway. This study will also be evaluated a boosting agent in place of Norvir, currently called GS9350. Elvitegravir holds promise for HIV-positive patients who have taken other anti-HIV drugs in the past. | ||
|- | |- | ||
| MK-2048 || - || [http://www.merck.com/ Merck & Co.] || - || A second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). | | [[MK-2048]] || - || [http://www.merck.com/ Merck & Co.] || - || A second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP). | ||
|- | |- | ||
|} | |} | ||
